Thomas Lienard has over 15 years of national and international sales and marketing experience in the pharmaceutical industry.
Prior to joining Bone Therapeutics, Thomas Lienard worked at Lundbeck, where he acted as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. He led a team of up to 80 employees, generating over EUR 50 million in sales. Before his position at Lundbeck, he worked at Eli Lilly and Company, where he held various positions in sales and marketing in Europe and the US, including Sales Director Belgium in 2010. Thomas Lienard started his career in 1999 as consultant at McKinsey & Company. He graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) from Harvard Business School in Boston in 2004.
Thomas Lienard joined Bone Therapeutics in 2015 as Chief Business Officer in charge of activities regarding business development and strategic planning and was appointed CEO in October 2016.
Wim Goemaere is an experienced senior financial executive with over 25 years international business experience, the majority of which he spent within the biotechnology field.
After graduating in applied economics from KU Leuven (Belgium) in 1987, he began his career at BP where he held various finance roles with increasing responsibility until leaving the Company in 1995, to join the Flanders Institute for Biotechnology (VIB) as CFO. He played a key role in the Institute's development from start-up to one of the world's leading research bodies in life sciences.
In 2008, Wim Goemaere moved to Devgen, a Belgium-based multinational agro-biotech company listed on NYSE Euronext Brussels, where he held the position of CFO for five years. He was instrumental in ensuring endorsement of Devgen in the financial markets and in the take-over of Devgen by Syngenta for €403 million. Furthermore, he played an important role into the company's business expansion in Asia.
Wim Goemaere has been the financial director of Bone Therapeutics since 2013.
Miguel Forte has significant regenerative medicine and cell therapy industry experience, most recently as Chief Operating and Medical Officer at TxCell, a French biotechnology company specializing in immune cell therapy, and as Chief Commercialization Officer and Chair of the Commercialization Committee at the International Society of Cellular Therapy (ISCT). With over 20 years’ industry experience, he has gained broad expertise in medical and regulatory affairs, ranging from leading early and late stage clinical trials to market authorization and the launch of new biologic products for various indications.
Prior to TxCell, Miguel Forte held several leadership positions in large pharmaceutical companies, including as Vice President, Global Medical Affairs at UCB, and various senior positions at the European Medicines Agency, Bristol-Myers Squibb, Abbott, and Wellcome Laboratories (now part of GSK).
Miguel Forte graduated in Medicine from the University of Lisbon, specializing in infectious diseases and obtained a PhD in Immunology at the University of Birmingham. He is currently Associate Professor in Health Sciences and Pharmacy at the University of Aveiro and the University of Lisbon.
Guy Heynen started his career at the Belgian National Foundation for Scientific Research and in research roles at University Hospital, Liège, Belgium where he received his degree in medicine. Dr. Heynen is a specialist in rheumatology and immunology, with extensive experience in both university medical practice and in the pharmaceutical industry.
He has over 35 years' experience in medical affairs and regulatory functions at national and international levels and has a particular focus on management, team building and leadership. The majority of his career has been with Pfizer Inc. where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer's disease drug Aricept and medical team leader for Pfizer's anti-inflammatory drug franchise based in New York, US. Guy Heynen also served as medical affairs director at Anbics AG, Switzerland from 2003-2006 and remains a regional medical monitor for Pfizer GmbH Berlin.
Benoît Champluvier joins from GlaxoSmithKline Vaccines, where he has more than 20 years’ experience of driving innovation and complex bioprocesses, supporting the development and launch of a number of new products. He graduated from the Université Catholique de Louvain (UCL) in 1984 with an engineering degree in agronomics and a degree in economics. He then started a PhD in agronomic sciences at the UCL and was a postdoctoral researcher at the Institut für Enzymtechnologie in Jülich, Germany. He started his career at Jungbunzlauer in 1992. He joined GSK in 1993 as junior scientist and subsequently held a number of senior roles, such as Director Downstream Process Technology, Coordinator New Technologies & GMP Pilot Plant.
Nora Meskini has over 19 years of experience in the execution and coordination of clinical trials. Prior to her position at Bone Therapeutics, she was Associate Director of the European Clinical Program at Cytori Therapeutics for three years. Earlier, she held positions as Program Director Clinical Operations EMEA and Senior Clinical Research Manager EMEA at Biosense Webster (Johnson & Johnson).